SCHEMBL6433337

SCHEMBL6433337

CCOC(=O)CN(CC(=O)OCC)C(=O)CCNC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.43
GAA P10253 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CTSK P43235 2/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10042462 0.87 TDP1 (0.47) TDP1GAAMEN1KMT2ACTSK
SCHEMBL8264461 0.86 TDP1 (0.46) TDP1GAAMEN1KMT2AHTT
SCHEMBL14586334 0.85 ALDH1A1 (0.45) TDP1GAAMEN1KMT2ACTSK
SCHEMBL1784924 0.84 CTSK (0.51) TDP1GAAMEN1KMT2ACTSK
SCHEMBL6290055 0.83 GAA (0.47) TDP1GAAMEN1KMT2AHTT
SCHEMBL14176770 0.83 TDP1 (0.41) TDP1GAAMEN1KMT2ACTSK
SCHEMBL5768805 0.83 ALDH1A1 (0.50) TDP1GAAMEN1KMT2AHTT
SCHEMBL12258798 0.82 TDP1 (0.48) TDP1GAAMEN1KMT2ACTSK
SCHEMBL14196596 0.82 CA12 (0.40) TDP1GAAMEN1KMT2ACTSK
SCHEMBL16140278 0.81 GAA (0.43) TDP1GAAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729030-B2 Peptides that bind to the erythropoietin receptor AFFYMAX, INC. (US) 2014-05-20 US disclosed
US-8642545-B2 Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD (CN) 2014-02-04 US disclosed
US-8642545-B2 Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof JIANGSU HANSOH PHARMACEUTICAL CO., LTD (CN) 2014-02-04 US disclosed
US-20130079283-A1 Erythropoitein Receptor Peptide Formulations and Uses AFFYMAX, INC. (US) 2013-03-28 US disclosed
US-8324159-B2 Erythropoietin receptor peptide formulations and uses AFFYMAX, INC. (US) 2012-12-04 US disclosed
US-8324159-B2 Erythropoietin receptor peptide formulations and uses AFFYMAX, INC. (US) 2012-12-04 US disclosed
US-20120165275-A1 Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules AFFYMAX, INC. (US) 2012-06-28 US disclosed
US-8106154-B2 Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules AFFYMAX, INC. (US) 2012-01-31 US disclosed
US-8106154-B2 Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules AFFYMAX, INC. (US) 2012-01-31 US disclosed
US-20110245176-A1 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR AFFYMAX, INC. (US) 2011-10-06 US disclosed
US-20090048166-A1 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR AFFYMAX, INC. (US) 2009-02-19 US disclosed
US-7414105-B2 Peptide dimer bonded to polyethylene glycol through amide groups; insufficient or defective red blood cell production AFFYMAX, INC. (US) 2008-08-19 US disclosed
US-7414105-B2 Peptide dimer bonded to polyethylene glycol through amide groups; insufficient or defective red blood cell production AFFYMAX, INC. (US) 2008-08-19 US disclosed
WO-2008095004-A2 NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES AFFYMAX, INC. (US) 2008-08-07 WO disclosed
US-20080090760-A2 Compositions and Methods for Inhibiting Cellular Proliferation HEMBROUGH TODD 2008-04-17 US disclosed
US-20080081783-A1 ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES AFFYMAX, INC. (US) 2008-04-03 US disclosed
US-20070203066-A1 Compositions and methods for inhibiting cellular proliferation ENTREMED, INC. 2007-08-30 US disclosed
US-20070104704-A1 Erythropoietin receptor peptide formulations and uses AFFYMAX, INC. (US) 2007-05-10 US disclosed
US-20070104704-A1 Erythropoietin receptor peptide formulations and uses AFFYMAX, INC. (US) 2007-05-10 US disclosed
US-20070032408-A1 Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165275-A1 Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules DNPEP, NGLY1, LNPEP TDP1 2025/4885GAA 1083/4885MEN1 833/4885
US-20090048166-A1 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR EPOR, PROKR1, EDNRB TDP1 4855/4885GAA 1929/4885MEN1 3831/4885
US-20110245176-A1 NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR EPOR, PROKR1, EDNRB TDP1 4855/4885GAA 1929/4885MEN1 3831/4885
US-20130079283-A1 Erythropoitein Receptor Peptide Formulations and Uses EPOR, MPL, PROKR1 TDP1 4849/4885GAA 2413/4885MEN1 1252/4885
US-20080090760-A2 Compositions and Methods for Inhibiting Cellular Proliferation MKI67, VEGFA, HDGF TDP1 4402/4885GAA 1565/4885MEN1 1098/4885
US-20080081783-A1 ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES EPOR, PROKR1, PROKR2 TDP1 4804/4885GAA 1752/4885MEN1 2467/4885
US-20070032408-A1 Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds NGLY1, YWHAZ, PAM TDP1 4727/4885GAA 1363/4885MEN1 1190/4885
US-20070104704-A1 Erythropoietin receptor peptide formulations and uses EPOR, PROKR1, PROKR2 TDP1 4804/4885GAA 1752/4885MEN1 2467/4885
US-20070203066-A1 Compositions and methods for inhibiting cellular proliferation MKI67, VEGFA, HDGF TDP1 4402/4885GAA 1565/4885MEN1 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.